Afra Darvishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Afra Darvishi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ali Alipour
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publications - Amirreza Naseri
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
4 shared publications - Hanieh Salehi-Pourmehr
Tabriz University of Medical Sciences
3 shared publications - Mahnaz Talebi
Neurosciences Research Center (NSRC) Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Nazli Asadi
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Negar Asiaban
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The correlation between serum markers of oxidative stress and fatigue and related factors in minimally disabled patients with relapsing-remitting multiple sclerosis
Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe correlation between serum markers of oxidative stress and fatigue and related factors in minimally disabled patients with relapsing-remitting multiple sclerosis
Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.
- 8 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106845
Antimuscarinics in multiple sclerosis: A systematic review
- 8 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106845
Antimuscarinics in multiple sclerosis: A systematic review
- Open Access
- 15 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-12
Serum markers and gastric cancer: an umbrella review
Early detection of gastric cancer (GC) is crucial for lowering the mortality risk and health burden. Since various biomarkers have been studied for the early diagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or predicting the risk. Following the PRISMA statement and Joanna Briggs Institute (JBI) Manual, PubMed, Scopus, and Web of Science were searched before August 31, 2023. English-language systematic reviews that assessed the association between serum markers and the presence of and/or predicting the risk of GC with or without meta-analyses were included in this umbrella review. The chosen reviews assessed serum markers in GC, and the quality assessment was conducted by the JBI critical appraisal tool for systematic reviews. From 1441 records that remained after removing the duplicates, only seven were selected. The investigated serum markers in the studies included SOD activity, selenium, adiponectin dickkopf-1, pepsinogens, and autoantibodies. The bias risk in most of the included reviews was appropriately low. Overall, the SOD activity, circulating adiponectin, and selenium are suggested to be lower in patients with GC. Serum dickkopf-1 and serum pepsinogen are also proposed as potential biomarkers for GC. Considering the great heterogeneity between the studies, the possibility of publication bias, and the limited number of the included studies further investigation is required. The explained serum biomarkers could be helpful for diagnosis and predicting GC; however, further well-designed large-scale investigation is needed to ensure their clinical applications.
- 15 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-12
Open AccessSerum markers and gastric cancer: an umbrella review
Early detection of gastric cancer (GC) is crucial for lowering the mortality risk and health burden. Since various biomarkers have been studied for the early diagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or predicting the risk. Following the PRISMA statement and Joanna Briggs Institute (JBI) Manual, PubMed, Scopus, and Web of Science were searched before August 31, 2023. English-language systematic reviews that assessed the association between serum markers and the presence of and/or predicting the risk of GC with or without meta-analyses were included in this umbrella review. The chosen reviews assessed serum markers in GC, and the quality assessment was conducted by the JBI critical appraisal tool for systematic reviews. From 1441 records that remained after removing the duplicates, only seven were selected. The investigated serum markers in the studies included SOD activity, selenium, adiponectin dickkopf-1, pepsinogens, and autoantibodies. The bias risk in most of the included reviews was appropriately low. Overall, the SOD activity, circulating adiponectin, and selenium are suggested to be lower in patients with GC. Serum dickkopf-1 and serum pepsinogen are also proposed as potential biomarkers for GC. Considering the great heterogeneity between the studies, the possibility of publication bias, and the limited number of the included studies further investigation is required. The explained serum biomarkers could be helpful for diagnosis and predicting GC; however, further well-designed large-scale investigation is needed to ensure their clinical applications.
- Open Access
- 29 September 2025
- Published by Maad Rayan Publishing Company in Biomedical Research Bulletin
- Vol. 3 (3) , 149-152
Shark-Derived Neuroprotective Agents for Neurodegenerative Diseases: From Molecular Pathways to Clinical Evidence
Neurodegenerative diseases, such as (but not limited to) Alzheimer’s disease and Parkinson’s disease, are a serious global health problem. Considering that the current treatments are primarily focused on symptom relief, it is necessary to find novel therapeutic approaches, including target therapies. Sharks have a special biochemical potential, and various neuroprotective agents can be derived from these animals. This review aims to evaluate and summarize the data available on shark-derived compounds in the case of neurodegeneration, explaining the molecular signatures and insights for novel therapies. Squalamine, trodusquemine, and single domain antibodies are the major products discussed in this paper. This review study further provides molecular pathways and clinical and animal data due to date, suggesting promising insights into more investigations in this field.
- 29 September 2025
- Published by Maad Rayan Publishing Company in Biomedical Research Bulletin
- Vol. 3 (3) , 149-152
Open AccessShark-Derived Neuroprotective Agents for Neurodegenerative Diseases: From Molecular Pathways to Clinical Evidence
Neurodegenerative diseases, such as (but not limited to) Alzheimer’s disease and Parkinson’s disease, are a serious global health problem. Considering that the current treatments are primarily focused on symptom relief, it is necessary to find novel therapeutic approaches, including target therapies. Sharks have a special biochemical potential, and various neuroprotective agents can be derived from these animals. This review aims to evaluate and summarize the data available on shark-derived compounds in the case of neurodegeneration, explaining the molecular signatures and insights for novel therapies. Squalamine, trodusquemine, and single domain antibodies are the major products discussed in this paper. This review study further provides molecular pathways and clinical and animal data due to date, suggesting promising insights into more investigations in this field.
- Open Access
- 26 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70572
MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging
Purpose: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.Method: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).Findings: The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.Conclusion: Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
- 26 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70572
Open AccessMicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [18F] AV45 and FDG PET Imaging
Purpose: Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.Method: Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).Findings: The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.Conclusion: Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
- 25 September 2023
- Published by Wiley in Neurourology and Urodynamics
- Vol. 43 (1) , 167-182
Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta‐analysis
Purpose: Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS). Our aim was to evaluate the efficacy and safety of desmopressin treatment on nocturia in patients with underlying neurological diseases.Methods: Studies were identified by electronic search of PubMed, Embase, Cochrane, CINAHL, and Google Scholar databases. Studies were considered if they provided information on the effectiveness and safety of desmopressin (1‐desamino‐8‐d‐arginine vasopressin, or DDAVP) in the treatment of nocturia and their participants had acquired neurological pathology. Two researchers independently extracted the articles using specified datasets, such as quality‐of‐study indicators. Statistical meta‐analysis was carried out using Review Manager (RevMan) 5.4 statistical software (Cochrane Collaboration).Results: Of a total of 1042 articles in the initial search, 14 studies were included. Most of the published papers were related to MS (n = 7), two were on spinal cord injury, and other conditions were neural tube defect, myelodysplasia, Parkinson's disease, stroke, and multiple system atrophy. Overall, a total of 200 patients (mostly females) were enrolled. Thirteen studies evaluated the intranasal formulation of desmopressin and one study evaluated oral desmopressin. A significant decrease in nocturia episodes was reported in seven studies evaluating this topic. An increase in the maximum hours of uninterrupted sleep was reported in the three studies in which this outcome was assessed. A significant reduction in the volume of nocturnal incontinence was found in one study. Three studies were eligible to include in the meta‐analysis. The results showed that desmopressin compared to placebo, significantly reduced nighttime urination (mean difference: −0.75, 95% CI: −1.10 to −0.41; p < 0.00001). The rate of adverse events ranged from 0% to 68.42%. The critical appraisal results for all trials showed that most of the studies had low or moderate quality.Conclusions: Our results emphasized desmopressin's safety and efficacy in reducing nocturia episodes, with transient adverse effects on neurological patients. However, the data were achieved from low or medium‐quality trials, and further well‐designed randomized controlled trials are needed.
- 25 September 2023
- Published by Wiley in Neurourology and Urodynamics
- Vol. 43 (1) , 167-182
Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: A systematic review and meta‐analysis
Purpose: Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS). Our aim was to evaluate the efficacy and safety of desmopressin treatment on nocturia in patients with underlying neurological diseases.Methods: Studies were identified by electronic search of PubMed, Embase, Cochrane, CINAHL, and Google Scholar databases. Studies were considered if they provided information on the effectiveness and safety of desmopressin (1‐desamino‐8‐d‐arginine vasopressin, or DDAVP) in the treatment of nocturia and their participants had acquired neurological pathology. Two researchers independently extracted the articles using specified datasets, such as quality‐of‐study indicators. Statistical meta‐analysis was carried out using Review Manager (RevMan) 5.4 statistical software (Cochrane Collaboration).Results: Of a total of 1042 articles in the initial search, 14 studies were included. Most of the published papers were related to MS (n = 7), two were on spinal cord injury, and other conditions were neural tube defect, myelodysplasia, Parkinson's disease, stroke, and multiple system atrophy. Overall, a total of 200 patients (mostly females) were enrolled. Thirteen studies evaluated the intranasal formulation of desmopressin and one study evaluated oral desmopressin. A significant decrease in nocturia episodes was reported in seven studies evaluating this topic. An increase in the maximum hours of uninterrupted sleep was reported in the three studies in which this outcome was assessed. A significant reduction in the volume of nocturnal incontinence was found in one study. Three studies were eligible to include in the meta‐analysis. The results showed that desmopressin compared to placebo, significantly reduced nighttime urination (mean difference: −0.75, 95% CI: −1.10 to −0.41; p < 0.00001). The rate of adverse events ranged from 0% to 68.42%. The critical appraisal results for all trials showed that most of the studies had low or moderate quality.Conclusions: Our results emphasized desmopressin's safety and efficacy in reducing nocturia episodes, with transient adverse effects on neurological patients. However, the data were achieved from low or medium‐quality trials, and further well‐designed randomized controlled trials are needed.